Capivasertib (TruqapTM) is used in combination with fulvestrant (FaslodexTM) for the treatment of patients with hormone-receptor-positive, human-epidermal-growth-factor-receptor-2-negative breast cancer with metastatic disease. This evidence concerns the gene EGFR and breast cancer.